Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jeremy Fraysse"'
Publikováno v:
EClinicalMedicine, Vol 25, Iss , Pp 100445- (2020)
Background: Nonalcoholic fatty liver disease (NAFLD) has reached high prevalence, paralleling the obesity pandemic. The aggressive form of the disease, nonalcoholic steatohepatitis (NASH), is characterized by fatty infiltration and inflammation of th
Externí odkaz:
https://doaj.org/article/85c6a455e0d2451cb31e75421ea2ee85
Publikováno v:
American Journal of Gastroenterology. 115:562-574
OBJECTIVES As the prevalence of nonalcoholic steatohepatitis (NASH) in the elderly population increases, healthcare resource utilization (HCRU) and costs are also predicted to rise substantially. METHODS This retrospective, observational cohort study
Autor:
Iris Liou, Mindie H. Nguyen, A. Burak Ozbay, Nicole Meyer, Geoffrey Dusheiko, Stuart C Gordon, Joseph K. Lim, Jeremy Fraysse
Publikováno v:
Hepatology (Baltimore, Md.)
Chronic hepatitis B (CHB) comorbidity data are limited. Using insurance claims databases, our aims were to determine the prevalence and incidence of nonliver comorbidities in CHB patients over time and the predictors of select comorbidities in CHB pa
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Elsevier, 2020, 25, pp.100445. ⟨10.1016/j.eclinm.2020.100445⟩
EClinicalMedicine, Vol 25, Iss, Pp 100445-(2020)
EClinicalMedicine, Elsevier, 2020, 25, pp.100445. ⟨10.1016/j.eclinm.2020.100445⟩
EClinicalMedicine, Vol 25, Iss, Pp 100445-(2020)
Background Nonalcoholic fatty liver disease (NAFLD) has reached high prevalence, paralleling the obesity pandemic. The aggressive form of the disease, nonalcoholic steatohepatitis (NASH), is characterized by fatty infiltration and inflammation of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0660e540cab4647ed8a35719259d0c86
https://hal.univ-angers.fr/hal-03284291
https://hal.univ-angers.fr/hal-03284291
Autor:
Jeremy Fraysse, Sanatan Shreay, Suying Li, Stephen A. Harrison, Rohit Loomba, Robert J. Wong, Stuart C. Gordon
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 51(11)
Autor:
Jeremy Fraysse, Stephen A. Harrison, Rohit Loomba, Robert J. Wong, Suying Li, Stuart C. Gordon, Sanatan Shreay
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 51(11)
BACKGROUND Risk factors and timing associated with disease progression and mortality in nonalcoholic fatty liver disease (NAFLD) are poorly understood. AIMS To evaluate the impact of disease severity, demographics and comorbidities on risk of mortali
Publikováno v:
Diabetes. 68
Background: DM patients have a 7-8 times higher risk of development of NASH with advanced fibrosis or cirrhosis than non-DM, which are predictors of mortality in NASH patients. This study evaluated mortality in NAFLD/NASH patients by liver disease se
Publikováno v:
Diabetes. 68
Background: One of the common comorbidities in NAFLD/NASH patients is DM. This study evaluated HCU and costs in NAFLD/NASH patients with varying liver disease severity by DM status. Methods: This was a retrospective study from 2007-2015 of a 20% samp
Publikováno v:
Journal of Hepatology. 70:e291-e292
Publikováno v:
Journal of Hepatology. 70:e36